A novel high-throughput screening assay to identify inhibitors of HIV-1 gp120 protein interaction with DC-SIGN

Journal of Antivirals and Antiretrovirals

Volumn 3, Issue 4, 2011, Pages 049-054

  Tran, Thuong H ^a   El Baz, Rasha ^a   Cuconati, Andrea ^b   Arthos, James ^c   Jain, Pooja ^a   Khan, Zafar K ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b BARUCH S BLUMBERG INSTITUTE   (United States)

^c National Institute of Allergy and Infectious Diseases   (United States)

Author keywords

DC SIGN; gp120; High throughput screening assay

Indexed keywords

BLOCKING ANTIBODY; CD209 ANTIGEN; CLONE 120507; GLYCOPROTEIN GP 120; SC 20; UNCLASSIFIED DRUG;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; HIGH THROUGHPUT SCREENING; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL NOISE RATIO; VALIDATION PROCESS;

EID: 84857185275     PISSN: None     EISSN: 19485964     Source Type: Journal    
DOI: 10.4172/jaa.1000035     Document Type: Article

References (36)

1. UNAIDS (2010) Global report: UNAIDS report on the global AIDS epidemic. UNAIDS, City.
2. Montessori V, Press N, Harris M, Akagi L, Montaner JS (2004) Adverse effects of antiretroviral therapy for HIV infection. CMAJ 170: 229-238.
3. O'Brien KL, Liu J, King SL, Sun YH, Schmitz JE, et al. (2009) Adenovirusspecific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 15: 873-875.
4. Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, et al. (2003) Medicine. The need for a global HIV vaccine enterprise. Science 300: 2036-2039.
5. Letvin NL (2005) Progress toward an HIV vaccine. Annu Rev Med 56: 213-223.
6. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, et al. (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763-767.
7. Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17: 657-700.
8. Dervillez X, Klaukien V, Durr R, Koch J, Kreutz A, et al. (2010) Peptide ligands selected with CD4-induced epitopes on native dualtropic HIV-1 envelope proteins mimic extracellular coreceptor domains and bind to HIV-1 gp120 independently of coreceptor usage. J Virol 84: 10131-10138.
9. Valenzuela A, Blanco J, Krust B, Franco R, Hovanessian AG (1997) Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and-independent binding of virus to cells. J Virol 71: 8289-8298.
10. Weinberg J, Liao HX, Torres JV, Matthews TJ, Robinson J, et al. (1997) Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4. AIDS Res Hum Retroviruses 13: 657-664.
11. Belyakov IM, Berzofsky JA (2004) Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 20: 247-253.
12. Piguet V, Blauvelt A (2002) Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease. J Invest Dermatol 119: 365-369.
13. Turville SG, Arthos J, Donald KM, Lynch G, Naif H, et al. (2001) HIV gp120 receptors on human dendritic cells. Blood 98: 2482-2488.
14. Geijtenbeek TB, Engering A and Van Kooyk Y (2002) DC-SIGN, a C-type lectin on dendritic cells that unveils many aspects of dendritic cell biology. J Leukoc Biol 71: 921-931.
15. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, et al. (2000) DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100: 587-597.
16. Lekkerkerker AN, Ludwig IS, van Vliet SJ, van Kooyk Y, Geijtenbeek TB (2004) Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120. Virology 329: 465-476.
17. Snyder GA, Ford J, Torabi-Parizi P, Arthos JA, Schuck P, et al. (2005) Characterization of DC-SIGN/R interaction with human immunodeficiency virus type 1 gp120 and ICAM molecules favors the receptor's role as an antigencapturing rather than an adhesion receptor. J Virol 79: 4589-4598.
18. Reuter MA, Pecora ND, Harding CV, Canaday DH, McDonald D (2010) Mycobacterium tuberculosis promotes HIV trans-infection and suppresses major histocompatibility complex class II antigen processing by dendritic cells. J Virol 84: 8549-8560.
19. Adema GJ, Hartgers F, Verstraten R, de Vries E, Marland G, et al. (1997) A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 387: 713-717.
20. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
21. Jameson B, Baribaud F, Pohlmann S, Ghavimi D, Mortari F, et al. (2002) Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J Virol 76: 1866-1875.
22. Geijtenbeek TB, van Kooyk Y (2003) DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr Top Microbiol Immunol 276: 31-54.
23. Arrighi JF, Pion M, Wiznerowicz M, Geijtenbeek TB, Garcia E, et al. (2004) Lentivirus-mediated RNA interference of DC-SIGN expression inhibits human immunodeficiency virus transmission from dendritic cells to T cells. J Virol 78: 10848-10855.
24. Nair MP, Reynolds JL, Mahajan SD, Schwartz SA, Aalinkeel R, et al. (2005) RNAi-directed inhibition of DC-SIGN by dendritic cells: prospects for HIV-1 therapy. AAPS J 7: 572-578.
25. Balzarini J, Van Herrewege Y, Vermeire K, Vanham G, Schols D (2007) Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol Pharmacol 71: 3-11.
26. Borrok MJ, Kiessling LL (2007) Non-carbohydrate inhibitors of the lectin DCSIGN. J Am Chem Soc 129: 12780-12785.
27. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
28. Aljofan M, Porotto M, Moscona A, Mungall BA (2008) Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus. J Virol Methods 149: 12-19.
29. Schon MP, Krahn T, Schon M, Rodriguez ML, Antonicek H, et al. (2002) Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med 8: 366-372.
30. Mitchell DA, Fadden AJ, Drickamer K (2001) A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J Biol Chem 276: 28939-28945.
31. Su SV, Hong P, Baik S, Negrete OA, Gurney KB, et al. (2004) DC-SIGN binds to HIV-1 glycoprotein 120 in a distinct but overlapping fashion compared with ICAM-2 and ICAM-3. J Biol Chem 279: 19122-19132.
32. Kampani K, Quann K, Ahuja J, Wigdahl B, Khan ZK, et al. (2007) A novel high throughput quantum dot-based fluorescence assay for quantitation of virus binding and attachment. J Virol Methods 141: 125-132.
33. Jain P, Manuel SL, Khan ZK, Ahuja J, Quann K, et al. (2009) DC-SIGN mediates cell-free infection and transmission of human T-cell lymphotropic virus type 1 by dendritic cells. J Virol 83: 10908-10921.
34. Rowlands MG, Newbatt YM, Prodromou C, Pearl LH, Workman P, et al. (2004) High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem 327: 176-183.
35. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P and Riscoe M (2004) Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother 48: 1803-1806.
36. van Kooyk Y, Geijtenbeek TB (2003) DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol 3: 697-709.